Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation

NCT01882374 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Change in drug product development strategy

Conditions

Hematologic Malignancies

Interventions

DRUG: TXA127

Sponsor

Tarix Pharmaceuticals